GSK Builds Case for Blenrep with Multiple Myeloma OS Data That Bests J&J’s Darzalex

GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects a multi-blockbuster potential for the antibody-drug conjugate.